Ahead of Merck (MRK) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Core Viewpoint - Analysts forecast Merck's quarterly earnings to be $2.16 per share, reflecting a year-over-year increase of 4.4%, while revenues are expected to decline by 1.9% to $15.48 billion [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 4%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Projections - Sales for Oncology product Keytruda are projected to reach $7.55 billion, an increase of 8.7% year-over-year [5]. - Hospital Acute Care sales for Zerbaxa are expected to be $63.07 million, reflecting a 12.6% increase from the previous year [5]. - Alliance revenue for Lynparza is estimated at $300.62 million, indicating a 3% increase year-over-year [5]. - Sales for Oncology Alliance revenue Lenvima are projected at $234.33 million, showing an 8.1% decline from the prior year [6]. - U.S. sales for Keytruda are expected to be $4.47 billion, reflecting an 8.6% increase year-over-year [6]. - International sales for Keytruda are projected at $3.08 billion, indicating an 8.8% increase from the previous year [7]. - U.S. sales for Lynparza are expected to reach $121.96 million, reflecting a 9.7% decline year-over-year [7]. - International sales for Lynparza are projected at $178.66 million, indicating a 13.8% increase from the prior year [8]. - U.S. sales for Lenvima are expected to be $155.59 million, reflecting a 10.1% decline year-over-year [8]. - International sales for Lenvima are projected at $78.74 million, indicating a 4% decline from the previous year [9]. - U.S. sales for Zerbaxa are expected to reach $36.81 million, reflecting an 11.5% increase year-over-year [9]. - International sales for Zerbaxa are projected at $26.26 million, indicating a 14.2% increase from the prior year [10]. Stock Performance - Merck's shares have decreased by 17.7% over the past month, compared to a 6.9% decline in the Zacks S&P 500 composite [10].